Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis - PubMed
3 hours ago
- #Daratumumab
- #AL amyloidosis
- #Clinical trial
- D-VCd (daratumumab-bortezomib-cyclophosphamide-dexamethasone) significantly improves hematologic complete response (CR) rate (59.5% vs. 19.2%) compared to VCd alone in newly diagnosed AL amyloidosis.
- Median time to hematologic CR is shorter with D-VCd (67.5 days) than with VCd (85.0 days).
- D-VCd shows significant improvement in major organ deterioration-progression-free survival (HR 0.44) and overall survival (HR 0.62) after a median follow-up of 61.4 months.
- Cardiac and renal response rates are 2-3 times higher with D-VCd compared to VCd.
- Achieving hematologic or cardiac CR is associated with improved survival outcomes.
- Adverse events align with known safety profiles for VCd and daratumumab.
- D-VCd is established as the only approved therapy for light-chain (AL) amyloidosis.